Catalyst
Slingshot members are tracking this event:
Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PRTK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 18, 2017
Related Projects
- Exploring Paratek's (PRTK) Lead Candidate, Omadacycline, for the Treatment of CABP (community acquired bacterial pneumonia) After the Phase 3 Data Readout PRTK, CEMP Executed On: Jul 21, 2017 at 02:00 PM EDT
Related Keywords
Bacterial Pneumonia Study, Omadacycline, Moxifloxacin
